In summary, we established a NY-BR-1 expressing tumor model in HLA-DR4tg mice and introduce the first NY-BR-1-specific, H2-Db-resctricted CD8+ T cell epitope, thus allowing investigation of NY-BR-1 as a target for therapeutic vaccination approaches against breast cancer in vivo. This evidence concerns the gene CD8A and neoplasm.